Abstract library

121 results for "OR51E1".
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#2727 Gastroenteropancreatic Neuroendocrine Tumours versus Gastroenteropancreatic Neuroendocrine Carcinoma: Presentation in Tunisian Patients
Introduction: Neuroendocrine neoplasms (NENs) are divided into two groups on the basis of clinical behaviour, histology, and proliferation rate: well differentiated (low grade to intermediate grade) neuroendocrine tumors and poorly differentiated (high grade) neuroendocrine carcinoma.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Imen Harhira
#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study
Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Massironi
#2811 Improving Diagnosis Times as Part of the Transformation of the South Wales NET Service
Introduction: Transformation of the South Wales NET service in late 2017 introduced new specialised staff, gastroenterology-led clinics and improved MDTs with a particular emphasis on educating referring specialties. This has led to improved overall patient experience, satisfaction and quality of life. NETs are recognised world-wide for their lengthy diagnosis times.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kapish Amin
#2812 SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Antonio Viudez
#2816 Germline Variants in Cancer Predisposing Genes in Young Adults with Neuroendocrine Tumors
Introduction: Advances in genomics have enabled the recognition of new cancer predisposing genes (CPG). There are few studies of CPG in neuroendocrine tumors (NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Prof Rachel Riechelmann
#2829 Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes
Introduction: The incidence and risk factors for everolimus-induced pneumonitis (EiP) have been poorly studied in patients (pts) with neuroendocrine neoplasms (NEN) outside of clinical trials.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Rodrigo G Taboada
#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry
Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Alberto Carmona-Bayonas
#2881 Patient-Derived Tumor Xenograft Combined with Chemotherapy Drug Sensitivity Test in a Patient with Pancreatic Neuroendocrine Carcinoma
Introduction: Pancreatic neuroendocrine carcinoma (p-NEC) with liver metastasis has a poor prognosis. The treatment is mainly chemotherapy which is now still a huge challenge on NEC with high ki-67 index.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Jian-An Bai
Authors: Bai J A, Tang Q, ...
#2882 Impact of Ga68-DOTATOC PET/MRI on Therapy Management in Patients with Neuroendocrine Neoplasia (NEN) - Preliminary Results
Introduction: Integrated PET/MRI combines the sensitivity and functional relevance of PET imaging and the spatial resolution and soft tissue contrast of MRI.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Piotr Radojewski